Synthesis and evaluation of analogs of Efavirenz (SUSTIVATM) as HIV-1 reverse transcriptase inhibitors
摘要:
Efavirenz (SUSTIVA(TM)) is a potent non-nucleoside reverse transcriptase inhibitor. Due to the observation of breakthrough mutations of the reverse transcriptase enzyme during Efavirenz therapy, we sought to develop an optimized second generation series. To that end, SAR of the substituents on the aromatic ring was undertaken and the results are summarized here. The 5,6-difluoro (4f) and the 6-methoxy (4m) substituted benzoxazinones were determined to be equipotent, and as a result such substitution patterns will be incorporated in second generation scaffolds. (C) 1999 DuPont Pharmaceuticals. Published by Elsevier Science Ltd. All rights reserved.
Cu(OTf)
<sub>2</sub>
‐Mediated Cross‐Coupling of Nitriles and N‐Heterocycles with Arylboronic Acids to Generate Nitrilium and Pyridinium Products**
作者:Nicola L. Bell、Chao Xu、James W. B. Fyfe、Julien C. Vantourout、Jeremy Brals、Sonia Chabbra、Bela E. Bode、David B. Cordes、Alexandra M. Z. Slawin、Thomas M. McGuire、Allan J. B. Watson
DOI:10.1002/anie.202016811
日期:2021.3.29
Metal‐catalyzed C–N cross‐coupling generally forms C−N bonds by reductive elimination from metalcomplexes bearing covalent C‐ and N‐ligands. We have identified a Cu‐mediated C–N cross‐coupling that uses a dative N‐ligand in the bond‐forming event, which, in contrast to conventional methods, generates reactive cationic products. Mechanistic studies suggest the process operates via transmetalation of
金属催化的 C-N 交叉偶联通常通过带有共价 C 和 N 配体的金属配合物的还原消除来形成 C-N 键。我们已经确定了一种 Cu 介导的 C-N 交叉偶联,该偶联在成键事件中使用了配位 N 配体,与传统方法相反,它会生成反应性阳离子产物。机理研究表明,该过程是通过芳基有机硼向带有中性 N 配体(例如腈或 N 杂环)的Cu II络合物的金属转移来进行的。随后生成的假定的 Cu III络合物使氧化 C-N 偶联发生,从而产生硝中间体和吡啶产物。该反应对于一系列 N(sp) 和 N(sp 2 ) 前体是通用的,可应用于药物合成和后期 N-芳基化,并且从机制上证明了该方法的局限性。
AMIDINE, THIOUREA AND GUANIDINE DERIVATIVES OF 2-AMINOBENZOTHIAZOLES AND AMINOBENZOTHIAZINES FOR THEIR USE AS PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE PATHOLOGIES
申请人:Anzini Maurizio
公开号:US20100197670A1
公开(公告)日:2010-08-05
Amidine, thiourea and guanidine derivatives of appropriately substituted 2-aminobenzothiazoles, 2-amino-3,1-4H-benzothiazines and 3-amino-1,4-3H-benzothiazines, as understood from formula (I), the related pharmaceutically acceptable salts and solvates thereof:
and the use of the products and the corresponding pharmaceutical formulations for the treatment of neurodegenerative pathologies such as cerebral ischemia, neurodegeneration induced by cranial trauma, Alzheimer's disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis.
[EN] AMIDINE, THIOUREA AND GUANIDINE DERIVATIVES OF 2-AMINOBENZOTHIAZOLES AND AMINOBENZOTHIAZINES FOR THEIR USE AS PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE PATHOLOGIES<br/>[FR] DÉRIVÉS AMIDINE, THIOURÉE ET GUANIDINE DE 2-AMINOBENZOTHIAZOLES ET D'AMINOBENZOTHIAZINES, NOUVEAUX AGENTS PHARMACOLOGIQUES POUR LE TRAITEMENT DES PATHOLOGIES NEURODÉGÉNÉRATIVES